Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $8.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 142.89% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $34.6 million (up 85.88% YoY), while the FY2025 annual figure was $9.0 million, up 113.56% from the prior year.
• Non-Current Assets was $8.6 million for Q1 2026 at Amylyx Pharmaceuticals, down from $9.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $52.8 million in Q4 2023 to a low of $3.5 million in Q1 2025.
• Historically, Non-Current Assets has averaged $13.4 million across 5 years, with a median of $9.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 1305.73% in 2022, then sank 92.04% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $9.3 million in 2022, then jumped by 466.39% to $52.8 million in 2023, then tumbled by 92.04% to $4.2 million in 2024, then jumped by 113.56% to $9.0 million in 2025, then fell by 4.4% to $8.6 million in 2026.
• The last three Non-Current Assets figures came in at $8.6 million (Q1 2026), $9.0 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.